Sildenafil may be better given to pulmonary arterial hypertension (PAH) patients in combination with ambrisentan than with bosentan, study findings suggest. Researcher Keiichi Odagiri (Hamamatsu ...

Studies focused on Asian populations with pulmonary arterial hypertension (PAH) treated with sildenafil are rare, and a new meta-analysis has found the phosphodiesterase-5 inhibitor effective in this ...

Future Cardiol. 2013;9(3):335-349. The pivotal trial that established sildenafil as a treatment for WHO Group 1 PH was the SUPER trial. [102] SUPER enrolled WHO functional class II and III PAH ...

(HONOLULU, HAWAII, OCTOBER 24, 2011) — Sildenafil is currently approved for adult pulmonary arterial hypertension (PAH); however, new research presented at CHEST 2011, the 77th annual meeting of the ...

Please provide your email address to receive an email when new articles are posted on . The Kids MoD PAH Trial is recruiting pediatric patients with newly diagnosed PAH. Sildenafil plus bosentan vs.

1 Genetic testing and professional genetic counseling should be offered to relatives of patients with familial PAH. Level of evidence: expert opinion; benefit: intermediate; grade of recommendation: E ...

The study used rats with monocrotaline (MCT)-induced PAH to examine whether adding dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, would offer any add-on benefit when used with ...